Chondroblastoma-like osteosarcoma: a case report and review

Aycan, Osman Emre; Vanel, D.; Righi, Alberto; Arıkan, Yavuz; Manfrini, Marco

doi:10.1007/s00256-014-2068-2

Cited by 20 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also report here the H3F3 mutational status of a tumor combining typical areas of chondroblastoma and areas of high-grade conventional osteosarcoma, with a sudden transition between the two components. In view of these tumors, very few cases of which have been described in the literature, 16,17 the diagnosis of malignant chondroblastoma rather than chondroblastoma-like osteosarcoma could be raised. This sample exhibited a rare mutation of H3F3A (K37M), never to our knowledge described in the other giant cell-rich tumors.…”

Section: Discussionmentioning

confidence: 99%

H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach

et al. 2017

View full text Add to dashboard Cite

Behjati et al recently described recurrent mutations of H3F3 genes in giant cell tumors of the bone and chondroblastomas. Both these entities belong to the spectrum of giant cell-rich bone lesions, often presenting a diagnostic challenge for the pathologist. Our aim was to investigate the value of searching for H3F3 mutations in the diagnosis of giant cell tumors of the bone and giant cell-rich chondroblastomas. Two hundred eighty-one bone lesion samples, including 170 giant cell tumors of the bone, 26 chondroblastomas and 85 other giant cell-rich and/or epiphyseal tumors, were analyzed. Mutation status was determined using first high resolution melting screening and then mutation profiling pyrosequencing. Mutational status was compared with clinical data and, for giant cell tumors of the bone, with p63 immunostaining status. As histone methylation changes have been reported in association with H3F3 mutations, the methylation status of lysine 37 was investigated. H3F3A and H3F3B were found in 85% of giant cell tumors of the bone and 88% of chondroblastomas. In addition to the major G35W mutation, we found two rare H3F3A mutations: one G35R and one G35V. Among the other tumors studied, we only found H3F3A gene mutations in two cases of 'dedifferentiated chondrosarcoma mimicking giant cell tumor of the bone'. A H3F3B mutation was also observed in one case of dedifferentiated chondroblastoma. P63 expression in giant cell tumors of the bone seems to be associated with H3F3 gene mutations (P=0.004). H3F3 mutations did not correlate with clinical data, outcome or methylation changes in Lysin 37. In conclusion, H3F3 mutations are sensitive and specific markers of giant cell tumors of the bone and chondroblastomas. High resolution melting and pyrosequencing procedures are high-performance tools in this context. Determination of H3F3 mutation will allow reclassification of some entities belonging to the spectrum of giant cell-rich lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Distinguishing these two neoplasms is vital for the delivery of appropriate clinical treatment, which involves neoadjuvant chemotherapy for patients with osteosarcoma. There is an exceptionally rare variant of osteosarcoma known as chondroblastoma‐like osteosarcoma: this tumour resembles the histological phenotype of its benign counterpart, but shows nuclear atypia and has a permeative growth pattern . Unfortunately, we have not had the opportunity to test such cases.…”

Section: Discussionmentioning

confidence: 99%

The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Osteosarcoma has a fatality rate of up to 80%, as well as high malignancy and invasive ability. Most cases are diagnosed during the late stage of the disease (Aycan et al, 2015;Liu et al, 2015b). Recent advances in chemotherapy, radiation therapy, biological therapy, and surgical technology have allowed a vast majority of osteosarcoma patients to receive limb salvage treatment.…”

Section: Introductionmentioning

confidence: 99%

Tim-3 facilitates osteosarcoma proliferation and metastasis through the NF-κB pathway and epithelial-mesenchymal transition

Feng¹,

Guo²

2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to investigate the expression of T-cell immunoglobulin mucin domain molecule-3 (Tim-3) in osteosarcoma tissues, and analyze its effect on cell proliferation and metastasis in an osteosarcoma cell line. Tim-3 mRNA and protein expression in osteosarcoma tissue was detected by reverse transcriptase-polymerase chain reaction and immunohistochemistry, respectively. Additionally, the cell viability, apoptosis rate, and invasive ability of the osteosarcoma cell line MG-63 were tested using the methyl thiazolyl tetrazolium assay, Annexin V-propidium iodide flow cytometry, and a Transwell assay, respectively, following Tim-3 interference using small interfering RNA (siRNA). We also analyzed the expression of Snail, E-cadherin, vimentin, and nuclear factor (NF)-kB in the cells by western blot. We observed that Tim-3 mRNA and protein was significantly overexpressed in osteosarcoma tissues, compared to the adjacent normal tissue (P < 0.01). Moreover, MG-63 cells transfected with the Tim-3 siRNA presented lower cell viability, a greater number of apoptotic cells, and decreased invasive ability (P < 0.01), compared to control cells. Additionally, we observed a decrease in Snail and vimentin expression, an increase in the E-cadherin level, and an increase in NF-kB p65 phosphorylation (P < 0.01) in Tim-3 siRNA-transfected MG-63 cells. Based on these results, we concluded that Tim-3 is highly expressed in osteosarcoma tissue. Moreover, we speculated that interfering in Tim-3 expression could significantly suppress osteosarcoma cell (MG-63) proliferation and metastasis via the NF-kB/Snail signaling pathway and epithelial-mesenchymal transition.

show abstract

Chondroblastoma-like osteosarcoma: a case report and review

Cited by 20 publications

References 22 publications

H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach

H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach

The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma

Tim-3 facilitates osteosarcoma proliferation and metastasis through the NF-κB pathway and epithelial-mesenchymal transition

Contact Info

Product

Resources

About